Non-small cell lung cancer (NSCLC), the predominant subtype, encapsulates an array of tumors that differ not only between patients but also within individual lesions. Among these, adenocarcinomas presenting as ground-glass opacities (GGOs) have emerged as especially noteworthy owing to their distinct...
In another study using 2D non-small-cell lung cancer (NSCLC) cell lines, neural net algorithms were used to create reference maps of lung cancer EMT and MET transition states59. Here we developed an organoid technology that allows PDAC organoids to acquire complex branched phenotypes reflecting ...
By sequencing and assembling a large genomic and transcriptomic dataset of lung adenocarcinoma (LUAD) in individuals of East Asian ancestry (EAS; n = 305), we found that East Asian LUADs had more stable genomes characterized by fewer mutations and fewer copy number alterations than LUADs ...
The first is the need to perform immunohistochemistry to further classify tumors formerly diagnosed as NSCLC not otherwise specified (NOS). Because the distinction between histologic types of lung cancer, particularly adenocarcinoma and squamous cell carcinoma, is so important, the new classification ...
NSCLC: Non-small cell lung cancer ChIP-seq: Chromatin immunoprecipitation followed by next-generation sequencing IF: Immunofluorescence FISH: Fluorescence in situ hybridization SMAD3: SMAD family member 3 CBP: CREB-binding protein P300: E1A-binding protein p300 RNA-seq: RNA sequencing ZEB...
The design of immunomodulatory strategies for the treatment of NSCLC will, however, tremendously benefit from a detailed understanding of the immune cell landscape that develops specifically in response to tumor cues. To this end, we developed a multiscale immune profiling strategy to map the immune...
NSCLC by loss of heterozygosity, somatic mutation, decreased expression, and increased alternative splicing into an oncogenic splice variant11. EGR1 had been shown to regulate genes influencing proliferation, apoptosis, immune cell activation, and matrix degradation, and so on. EGR1 levels increased ...
Immune checkpoint therapy, particularly anti-programmed cell death receptor-1 (PD-1)/anti-programmed cell death ligand-1 (PD-L1) antibody, is a novel cancer therapy and has become the standard therapy for a variety of tumors, including non-small cell lung cancer (NSCLC)6,7,8. Nevertheless,...
About 40 % of non-small cell lung cancer (NSCLC), one of two main categories of lung cancer is lung adenocarcinoma (LUAD) [12,13]. In recent years, an increasing number of researches have focused their attentions on the role of pivotal ion channel genes in LUAD [[14], [15], [16...
Programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) are target molecules for immunotherapy in non-small cell lung cancer. PD-L1 is expressed not only in cancer cells, but also on macrophages, and has been suggested to contribute to macrophage-mediated immune suppression. We examined...